Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Gadofosveset
Drug ID BADD_D00987
Description Gadofosveset trisodium is an intravenous contrast agent used with magnetic resonance angiography(MRA), which is a non-invasive way of imaging blood vessels. The agent allows for the vascular system to be imaged more clearly by the MRA. In this way, gadofosveset trisodium is used to help diagnose certain disorders of the heart and blood vessels.
Indications and Usage Gadofosveset trisodium is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.
Marketing Status approved
ATC Code V08CA11
DrugBank ID DB06705
KEGG ID D08005
MeSH ID C109932
PubChem ID 46174086
TTD Drug ID D0H0WK
NDC Product Code Not Available
UNII E65RW73PHS
Synonyms gadofosveset trisodium | gadofosveset | MS 325 | MS-325 | Vasovist
Chemical Information
Molecular Formula C33H41GdN3O14P
CAS Registry Number 193901-90-5
SMILES [H+].[H+].[H+].C1CC(CCC1OP(=O)([O-])OCC(CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-]) N(CC(=O)[O-])CC(=O)[O-])(C2=CC=CC=C2)C3=CC=CC=C3.[Gd+3]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypokalaemia14.05.03.002--
Hypotension24.06.03.002--
Immune system disorder10.02.01.001--Not Available
Infection11.01.08.002--Not Available
Injection site bruising24.07.06.017; 23.03.11.015; 12.07.03.042; 08.02.03.042--Not Available
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.001--Not Available
Injection site extravasation12.07.03.002; 08.02.03.002--Not Available
Injection site haemorrhage12.07.03.005; 08.02.03.005; 24.07.01.010--Not Available
Injection site inflammation12.07.03.009; 08.02.03.008--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site pruritus23.03.12.007; 12.07.03.014; 08.02.03.013--Not Available
Injection site thrombosis08.02.03.028; 24.01.01.023; 12.07.03.028--Not Available
Lacrimation increased06.08.02.004--
Laryngeal pain22.12.03.010--
Microalbuminuria20.02.01.026; 14.07.02.002; 05.07.02.002--Not Available
Micturition urgency20.02.02.006--
Muscle contractions involuntary17.05.03.001; 15.05.03.008--Not Available
Muscle spasms15.05.03.004--
Myocardial ischaemia24.04.04.010; 02.02.02.008--Not Available
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Neck pain15.03.04.009--
Nervous system disorder17.02.10.001--Not Available
Pain08.01.08.004--
Pain in extremity15.03.04.010--
Palpitations02.11.04.012--
Paraesthesia23.03.03.094; 17.02.06.005--
Parosmia22.04.03.007; 17.04.04.002--Not Available
Pelvic pain21.10.01.001; 20.02.03.007; 07.01.06.012--
Peripheral coldness08.01.09.010; 23.06.04.008; 24.04.03.006--Not Available
The 3th Page    First    Pre   3 4 5    Next   Last    Total 5 Pages